ESR1 and breast cancer: This study also found that 75% of E2-induced AR-binding sites overlapped with ER-binding sites and surprisingly, when MCF-7 cells (breast cancer cell line) were treated with enzalutamide or MJC13, the genomic binding of ER was only inhibited at those overlapping sites [21], which implies that AR may facilitate ER binding at those loci.